Abingworth closes new biotech fund at €268m
Bioscience investment firm Abingworth has closed its latest fund at US$315m (€268m). The money will go to life sciences companies in Europe and the US.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 238 entries already.
Entries by Uta Mommert
€47m for rare disease biotech
After €7m went to Nextbiotix last week, another financing round is bringing money to a young French biotech. Strasbourg-based Dynacure attracted €47m from investors to bring its lead candidate for centronuclear myopathy into clinical development.
€7m for French microbiome start-up
Microbiome start-up Nextbiotix raised € 7m in a Series A round. The Paris-based biotech uses commensal bacteria as drugs to treat major inflammatory bowel diseases.
Highs and lows for Fresenius Medical Care
Dialysis product and service provider Fresenius Medical Care has placed €500m notes. Yesterday, the medtech giant had to come to terms with a sharp drop in share price.
ReadyTector Immunodetection
ReadyTector is an easy, quick and clear all-in-one detection solution for Western blotting.
Eppendorf BioFlo 320 Universal Bioprocess Control Station
Whether your process includes cell culture or fermentation, autoclavable or single-use vessels, the BioFlo 320 seamlessly combines form and function in one state of the art package.
Preventing congestion in acute heart failure patients
German Adrenomed AG has decided to start clinical Phase II tests of the very first personalised treatment for the six million patients with acute congestive heart failure. Large trials suggest that the company can stratify patients resistant to diuretics standard therapy by a proprietary companion diagnostics blood test. Adrenomed will assess whether its first-in-class antibody adrecizumab can reverse the congestion that that manifests as pulmonary edema.
Euronext-listed Argenx plans €68.6m IPO in the US
Belgian-Dutch antibody developer Argenx N.V. seeks to raise US$74.7m in a US IPO. The company, which is already listed on Euronext wants to use the proceeds to push development of its autoimmune and cancer drugs.
Longevity: Healthy ageing
Italian, Swedish, and German researchers have started recruitment for a systematic investigation into the factors affecting longevity.
Blood cancer: Boosting chemotherapy effects
German and Swedish researchers have presented a strategy to predict and improve chemotherapy outcomes in patients with acute myelogenous leukaemia (AML). Currently, the five-year overall survival rate of AML patients treated with cytarabine (ara-C) standard chemotherapy ranges from 20-70%.